person · Reporting owner

Huber Martin H. Jr.

Disclosed activity across 5 companies

Tapewire entity: 44725
SEC CIK: 0001653276

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACTUATE THERAPEUTICS, INC.ACTU · Entity 7370	Director	May 21, 2026	May 22, 2026
Syndax Pharmaceuticals IncSNDX · Entity 4578	Director	February 04, 2026	February 06, 2026
Xilio Therapeutics, Inc.XLO · Entity 7122	PRESIDENT AND HEAD OF R&D	August 16, 2023	August 19, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACTUATE THERAPEUTICS, INC.

Report date May 21, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.42 · Expires 2036-05-21	Direct	15,000	Reported balance After 2026-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-21 · Grant · Acquired 15,000 · Balance 15,000 F1: Options will vest in full on the anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Options will vest in full on the anniversary of the grant date.

Syndax Pharmaceuticals Inc

Report date February 04, 2026 · Filed February 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	103,000	Reported balance After 2026-02-04 transaction · row 1 1 source row Row 1 · 2026-02-04 · Grant · Acquired 24,000 · Balance 103,000 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Filing footnotes · ownership attribution and instrument terms

F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Xilio Therapeutics, Inc.

Report date August 16, 2023 · Filed August 19, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2033-08-15	Direct	136,500	Reported balance After 2023-08-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-08-16 · Grant · Acquired 136,500 · Balance 136,500 F1: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Mersana Therapeutics, Inc.

Report date January 06, 2026 · Filed January 06, 2026

Section 16 reporting ended · disclosed 2026-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-01-06 transaction · row 1 1 source row Row 1 · 2026-01-06 · Other · Disposed 9,573 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01	Direct	Reported balance After 2026-01-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-06 · Disposition to issuer · Disposed 5,938 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01	Direct	Reported balance After 2026-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-01-06 · Disposition to issuer · Disposed 26,713 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $214.25	Direct	Reported balance After 2026-01-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-06 · Disposition to issuer · Disposed 1,923 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $527.25	Direct	Reported balance After 2026-01-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-06 · Disposition to issuer · Disposed 99 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $372.50	Direct	Reported balance After 2026-01-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-06 · Disposition to issuer · Disposed 1,002 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.00	Direct	Reported balance After 2026-01-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-06 · Disposition to issuer · Disposed 407 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.50	Direct	Reported balance After 2026-01-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-01-06 · Disposition to issuer · Disposed 1,800 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.25	Direct	Reported balance After 2026-01-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-01-06 · Disposition to issuer · Disposed 135 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $216.00	Direct	Reported balance After 2026-01-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-01-06 · Disposition to issuer · Disposed 734 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.50	Direct	Reported balance After 2026-01-06 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-01-06 · Disposition to issuer · Disposed 179 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.00	Direct	Reported balance After 2026-01-06 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-01-06 · Disposition to issuer · Disposed 12,121 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.00	Direct	Reported balance After 2026-01-06 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-01-06 · Disposition to issuer · Disposed 27,878 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.50	Direct	Reported balance After 2026-01-06 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-01-06 · Disposition to issuer · Disposed 364 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.50	Direct	Reported balance After 2026-01-06 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2026-01-06 · Disposition to issuer · Disposed 497 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.50	Direct	Reported balance After 2026-01-06 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2026-01-06 · Disposition to issuer · Disposed 7,467 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2026-01-06 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2026-01-06 · Disposition to issuer · Disposed 13,340 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2026-01-06 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2026-01-06 · Disposition to issuer · Disposed 1,328 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2026-01-06 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2026-01-06 · Disposition to issuer · Disposed 7,256 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

TESARO, Inc.

Report date January 22, 2019 · Filed January 22, 2019

Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-01-22 transaction · row 1 1 source row Row 1 · 2019-01-22 · Other · Disposed 12,206 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-01-22 · Disposition to issuer · Disposed 1,250 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-01-22 · Disposition to issuer · Disposed 8,750 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-01-22 · Disposition to issuer · Disposed 4,447 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-01-22 · Disposition to issuer · Disposed 22,727 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.14 · Expires 2025-09-21	Direct	Reported balance After 2019-01-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-01-22 · Disposition to issuer · Disposed 75,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.39 · Expires 2026-03-01	Direct	Reported balance After 2019-01-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-01-22 · Disposition to issuer · Disposed 35,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $178.95 · Expires 2027-03-01	Direct	Reported balance After 2019-01-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-01-22 · Disposition to issuer · Disposed 10,782 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2028-03-01	Direct	Reported balance After 2019-01-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-01-22 · Disposition to issuer · Disposed 39,942 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Filing footnotes · ownership attribution and instrument terms

F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").

F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 22, 2022 Filed Feb 24, 2022 22:30 UTC	Xilio Therapeutics, Inc. XLO · Entity 7122	GrantStock Option (right to buy) · Derivative	65,000	$0.00 Strike: $12.66	$0.00	Disclosure SEC source: 0001415889-22-001792 · form4-02242022_050208.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · PRESIDENT OF R&D AND CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-02-21 F1 · derivative.exercise_date: The option award was granted on February 22, 2022 and shall vest on March 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until February 1, 2026. Read SEC document
February 02, 2022 Filed Feb 3, 2022 22:28 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	16,000	$0.00	$0.00	Disclosure SEC source: 0001562180-22-001069 · primarydocument.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document
January 03, 2022 Filed Jan 5, 2022 22:05 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	10,185	$0.00 Strike: $6.44	$0.00	Disclosure SEC source: 0001104659-22-001558 · tm221771-5_4seq1.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,185 Underlying: Common Stock · 10,185 shares Expires 2032-01-02 F1 · derivative.exercise_date: The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2022. Read SEC document
October 21, 2021 Filed Oct 25, 2021 21:17 UTC	Xilio Therapeutics, Inc. XLO · Entity 7122	GrantStock Option (right to buy) · Derivative	157,058	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001104659-21-129570 · tm2130646-21_4seq1.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · President of R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,058 Underlying: Common Stock · 157,058 shares Expires 2031-10-20 F1 · derivative.exercise_date: The option award was granted on October 21, 2021 and will begin to vest on November 1, 2021 and continue to vest in equal monthly installments thereafter until October 1, 2025. Read SEC document
September 15, 2021 Filed Sep 17, 2021 20:32 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Options (Right to buy) · Derivative	35,000	$19.36 Strike: $19.36	$677,600.00	Disclosure SEC source: 0001562180-21-006002 · primarydocument.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-09-15 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document
June 11, 2021 Filed Jun 15, 2021 22:01 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	25,050	$0.00 Strike: $14.90	$0.00	Disclosure SEC source: 0001104659-21-081606 · tm2119714-1_4seq1.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,050 Underlying: Common Stock · 25,050 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2022 Annual Meeting of Stockholders of Mersana Therapeutics, Inc. Read SEC document
January 15, 2021 Filed Jan 21, 2021 00:02 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	2,490	$0.00 Strike: $21.09	$0.00	Disclosure SEC source: 0001104659-21-005944 · tm211948-5_4seq1.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 Underlying: Common Stock · 2,490 shares Expires 2031-01-15 F1 · derivative.exercise_date: The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2021. Read SEC document
April 13, 2020 Filed Jun 24, 2020 21:07 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy · Derivative	48,096	$0.00 Strike: $8.57	$0.00	Disclosure SEC source: 0001104659-20-076483 · a4.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,096 Underlying: Common Stock · 48,096 shares Expires 2030-04-13 F1 · derivative.exercise_date: The option becomes exercisable in equal quarterly installments over three years from the date of the grant. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:57 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	39,942	Not disclosed Strike: $55.84	Not disclosed	Disclosure SEC source: 0001123292-19-000168 · edgar.xml · derivative · entry 9 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,942 shares Expires 2028-03-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:57 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	10,782	Not disclosed Strike: $178.95	Not disclosed	Disclosure SEC source: 0001123292-19-000168 · edgar.xml · derivative · entry 8 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,782 shares Expires 2027-03-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:57 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	35,000	Not disclosed Strike: $43.39	Not disclosed	Disclosure SEC source: 0001123292-19-000168 · edgar.xml · derivative · entry 7 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2026-03-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:57 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	75,000	Not disclosed Strike: $55.14	Not disclosed	Disclosure SEC source: 0001123292-19-000168 · edgar.xml · derivative · entry 6 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2025-09-21 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:57 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerRestricted Stock Units · Derivative	22,727	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000168 · edgar.xml · derivative · entry 5 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,727 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:57 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerRestricted Stock Units · Derivative	4,447	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000168 · edgar.xml · derivative · entry 4 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,447 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:57 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerRestricted Stock Units · Derivative	8,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000168 · edgar.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:57 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerRestricted Stock Units · Derivative	1,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000168 · edgar.xml · derivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:57 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	12,206	$75.00	$915,450.00	Disclosure SEC source: 0001123292-19-000168 · edgar.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). Read SEC document
September 24, 2018 Filed Sep 25, 2018 18:00 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	371	$37.63	$13,960.73	Disclosure SEC source: 0001104659-18-058485 · a4.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,206 F1 · kind: This sale was effected in accordance with the terms of the underlying restricted stock unit award agreement and a 10b5-1 trading plan entered into by the Reporting Person and was made in order to pay the tax liability arising from the vesting of the restricted stock units. Read SEC document
September 21, 2018 Filed Sep 25, 2018 18:00 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	1,250	$0.00	$0.00	Disclosure SEC source: 0001104659-18-058485 · a4.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · derivative.exercise_date: The restricted stock units were granted on September 21, 2015, and vest in four equal annual installments beginning September 21, 2016. F3 · derivative.expiration_date: The restricted stock units were granted on September 21, 2015, and vest in four equal annual installments beginning September 21, 2016. Read SEC document
September 21, 2018 Filed Sep 25, 2018 18:00 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	1,250	$0.00	$0.00	Disclosure SEC source: 0001104659-18-058485 · a4.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 02, 2018 Filed Mar 5, 2018 17:25 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	1,803	$54.86	$98,912.58	Disclosure SEC source: 0001104659-18-014884 · a4.xml · nonDerivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,327 F1 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. F2 · price: The price reported is a weighted average. The shares were sold in multiple transactions at prices ranging from $54.30 to $54.86, inclusive. The reporting person undertakes to provide to TESARO, any security holder of TESARO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:25 UTC	TESARO, Inc. TSRO · Entity 160894	GrantEmployee Stock Option (right to buy) · Derivative	39,942	$0.00 Strike: $55.84	$0.00	Disclosure SEC source: 0001104659-18-014884 · a4.xml · derivative · entry 7 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,942 Underlying: Common Stock · 39,942 shares Expires 2028-03-01 F7 · derivative.exercise_date: The option vests in 48 equal monthly installments beginning on April 1, 2018. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:25 UTC	TESARO, Inc. TSRO · Entity 160894	GrantRestricted Stock Units · Derivative	22,727	$0.00	$0.00	Disclosure SEC source: 0001104659-18-014884 · a4.xml · derivative · entry 6 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock · 22,727 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F6 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on March 1, 2019. F6 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on March 1, 2019. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:25 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	1,483	$0.00	$0.00	Disclosure SEC source: 0001104659-18-014884 · a4.xml · derivative · entry 5 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,447 Underlying: Common Stock · 1,483 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F5 · derivative.exercise_date: The RSUs were granted on March 1, 2017, and the remaining RSUs vest in three equal annual installments on each of March 1, 2019, 2020 and 2021. F5 · derivative.expiration_date: The RSUs were granted on March 1, 2017, and the remaining RSUs vest in three equal annual installments on each of March 1, 2019, 2020 and 2021. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:25 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	4,375	$0.00	$0.00	Disclosure SEC source: 0001104659-18-014884 · a4.xml · derivative · entry 4 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 4,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4 · derivative.exercise_date: The RSUs were granted on March 1, 2016, and the remaining RSUs vest in two equal annual installments on each of March 1, 2019 and 2020. F4 · derivative.expiration_date: The RSUs were granted on March 1, 2016, and the remaining RSUs vest in two equal annual installments on each of March 1, 2019 and 2020. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:25 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	1,483	$0.00	$0.00	Disclosure SEC source: 0001104659-18-014884 · a4.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:25 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	4,375	$0.00	$0.00	Disclosure SEC source: 0001104659-18-014884 · a4.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 04, 2017 Filed Dec 5, 2017 18:10 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	829	$85.24	$70,663.96	Disclosure SEC source: 0001104659-17-071945 · a4.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,272 F3 · kind: This sale was effected in accordance with the terms of the underlying restricted stock unit award agreement and was made in order to pay the tax liability arising from the vesting of the restricted stock units. Read SEC document
December 01, 2017 Filed Dec 5, 2017 18:10 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	1,750	$0.00	$0.00	Disclosure SEC source: 0001104659-17-071945 · a4.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F1 · derivative.exercise_date: On July 27, 2016, the reporting person was granted 1,750 restricted stock units, all of which vested on December 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria. F1 · derivative.expiration_date: On July 27, 2016, the reporting person was granted 1,750 restricted stock units, all of which vested on December 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria. Read SEC document
December 01, 2017 Filed Dec 5, 2017 18:10 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	1,750	$0.00	$0.00	Disclosure SEC source: 0001104659-17-071945 · a4.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 27, 2016, the reporting person was granted 1,750 restricted stock units, all of which vested on December 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria. F2 · price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. Read SEC document
November 16, 2017 Filed Nov 20, 2017 17:51 UTC	TESARO, Inc. TSRO · Entity 160894	GrantRestricted Stock Units · Derivative	1,750	$0.00	$0.00	Disclosure SEC source: 0001104659-17-069672 · a4.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of common stock. F2 · derivative.exercise_date: The restricted stock units fully vest on December 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria. F2 · derivative.expiration_date: The restricted stock units fully vest on December 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria. Read SEC document
September 22, 2017 Filed Sep 25, 2017 17:44 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	592	$118.60	$70,211.20	Disclosure SEC source: 0001104659-17-058681 · a4.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,351 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of the restricted stock units. Read SEC document
September 21, 2017 Filed Sep 25, 2017 17:44 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	1,250	$0.00	$0.00	Disclosure SEC source: 0001104659-17-058681 · a4.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · derivative.exercise_date: On September 21, 2015, the reporting person was granted 5,000 restricted stock units, vesting in in four equal annual installments beginning September 21, 2016. F3 · derivative.expiration_date: On September 21, 2015, the reporting person was granted 5,000 restricted stock units, vesting in in four equal annual installments beginning September 21, 2016. Read SEC document
September 21, 2017 Filed Sep 25, 2017 17:44 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	1,250	$0.00	$0.00	Disclosure SEC source: 0001104659-17-058681 · a4.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. Read SEC document
April 03, 2017 Filed Apr 4, 2017 18:16 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	829	$153.02	$126,853.58	Disclosure SEC source: 0001104659-17-021464 · a4.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · SVP & Cheif Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,693 F3 · kind: This sale was effected in accordance with the terms of the underlying restricted stock unit award agreement and was made in order to pay the tax liability arising from the vesting of the restricted stock units. Read SEC document
April 01, 2017 Filed Apr 4, 2017 18:16 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	1,750	$0.00	$0.00	Disclosure SEC source: 0001104659-17-021464 · a4.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · SVP & Cheif Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represented the right to receive one share of common stock. F1 · derivative.exercise_date: The restricted stock units fully vested on April 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria. F1 · derivative.expiration_date: The restricted stock units fully vested on April 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria. Read SEC document
April 01, 2017 Filed Apr 4, 2017 18:16 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	1,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-17-021464 · a4.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Cheif Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units fully vested on April 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria. F2 · price: Each restricted stock unit represented the right to receive one share of common stock. Read SEC document
March 27, 2017 Filed Mar 29, 2017 21:28 UTC	TESARO, Inc. TSRO · Entity 160894	GrantRestricted Stock Units · Derivative	1,750	$0.00	$0.00	Disclosure SEC source: 0001104659-17-020070 · a4.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of common stock. F2 · derivative.exercise_date: The restricted stock units fully vest on April 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria. F2 · derivative.expiration_date: The restricted stock units fully vest on April 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria. Read SEC document
March 02, 2017 Filed Mar 3, 2017 17:17 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	1,428	$177.61	$253,627.08	Disclosure SEC source: 0001104659-17-014111 · a4.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,772 F1 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document
March 01, 2017 Filed Mar 3, 2017 17:17 UTC	TESARO, Inc. TSRO · Entity 160894	GrantEmployee Stock Option (right to buy) · Derivative	10,782	$0.00 Strike: $178.95	$0.00	Disclosure SEC source: 0001104659-17-014111 · a4.xml · derivative · entry 5 Huber Martin H. Jr. · CIK 0001653276 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,782 Underlying: Common Stock · 10,782 shares Expires 2027-03-01 F5 · derivative.exercise_date: The option vests in 48 equal monthly installments beginning on April 1, 2017. Read SEC document
March 01, 2017 Filed Mar 3, 2017 17:17 UTC	TESARO, Inc. TSRO · Entity 160894	GrantRestricted Stock Units · Derivative	5,930	$0.00	$0.00	Disclosure SEC source: 0001104659-17-014111 · a4.xml · derivative · entry 4 Huber Martin H. Jr. · CIK 0001653276 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,930 Underlying: Common Stock · 5,930 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2018. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2018. Read SEC document
March 01, 2017 Filed Mar 3, 2017 17:17 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	4,375	$0.00	$0.00	Disclosure SEC source: 0001104659-17-014111 · a4.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 4,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · derivative.exercise_date: The restricted stock units were granted on March 1, 2016 and vest in four equal annual installments beginning on March 1, 2017. F3 · derivative.expiration_date: The restricted stock units were granted on March 1, 2016 and vest in four equal annual installments beginning on March 1, 2017. Read SEC document
March 01, 2017 Filed Mar 3, 2017 17:17 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	4,375	$0.00	$0.00	Disclosure SEC source: 0001104659-17-014111 · a4.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2017 Filed Jan 3, 2017 18:35 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	190	$136.26	$25,889.40	Disclosure SEC source: 0001104659-17-000315 · a4.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F2 · kind: This sale was effected in accordance with the terms of the underlying restricted stock unit award agreement and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document
January 01, 2017 Filed Jan 3, 2017 18:35 UTC	TESARO, Inc. TSRO · Entity 160894	GrantCommon Stock	500	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-17-000315 · a4.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F1 · price: Represents the vesting of restricted stock units following satisfaction of certain performance criteria. Each restricted stock unit represents the right to receive one share of common stock. Read SEC document
November 02, 2016 Filed Nov 3, 2016 18:27 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	327	$121.29	$39,661.83	Disclosure SEC source: 0001104659-16-154687 · a4.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,515 F2 · kind: This sale was effected in accordance with the terms of the underlying restricted stock unit award agreement and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document
November 01, 2016 Filed Nov 3, 2016 18:27 UTC	TESARO, Inc. TSRO · Entity 160894	GrantCommon Stock	1,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-154687 · a4.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,842 F1 · price: Represents the vesting of restricted stock units following satisfaction of certain performance criteria. Each restricted stock unit represents the the right to receive one share of common stock. Read SEC document
September 22, 2016 Filed Sep 23, 2016 20:50 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	408	$108.12	$44,112.96	Disclosure SEC source: 0001104659-16-146349 · a4.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document
September 21, 2016 Filed Sep 23, 2016 20:50 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	1,250	$0.00	$0.00	Disclosure SEC source: 0001104659-16-146349 · a4.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On September 21, 2015, the reporting person was granted 5,000 restricted stock units, vesting in in four equal annual installments beginning September 21, 2016. F3 · derivative.expiration_date: On September 21, 2015, the reporting person was granted 5,000 restricted stock units, vesting in in four equal annual installments beginning September 21, 2016. Read SEC document
September 21, 2016 Filed Sep 23, 2016 20:50 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	1,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-146349 · a4.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.